134 results about "Mouse Macrophage" patented technology

New triterpenoid derivatives with various substituents at the C-17 position of 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid (CDDO) were synthesized. Among them, 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-onitrile (CNDDO), 1-(2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl) imidazole, 1-(2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl)-2-methylimidazole, 1-(2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl)-4-methylimidazole show extremely high inhibitory activity (IC50=0.01-1 pM level) against production of nitric oxide induced by interferon-γ in mouse macrophages. These compounds can be used in the prevention or treatment of diseases such as cancer, Alzheimer's disease, Parkinson's disease, multiple sclerosis, rheumatoid arthritis, and other inflammatory diseases. All the new triterpenoid derivatives are more potent than previously known CDDO.

This invention reveals the beneficial use of vitamin E tocotrienols for inhibition of chlamydial infections. Chlamydial infection levels in mouse macrophages treated with tocotrienol were decreased >50%, with concomitant aberrant pathogen development. The number of large and small inclusions in tocotrienol-versus-control cells was decreased 3-fold and 2-fold, respectively. When treated with delta tocotrienol, Chlamydia in human lymphocytes was inhibited by at least 2.6-fold in 1.5 days. Dietary delta tocotrienol inhibited Chlamydia infection and persistence in hypercholesterolemic patients with a corresponding drop in LDL. These studies demonstrate that tocotrienol lowers cholesterol, thus preventing or diminishing the cholesterol hijacking by Chlamydia obligatory for its infectivity and replication. Therefore, hypolipidemic agents used to treat cardiovascular diseases, metabolic syndrome, and diabetes are used as monotherapies, or in combination with tocotrienol to treat Chlamydia.

The invention discloses an application of a nanogold-carbon nano tube-chitosan composite membrane cell sensor to detection of toxicity of food-borne pathogenic bacteria and belongs to the technical field of detection of toxicity of Gram-negative pathogenic bacteria. According to the application, a magnetic glassy carbon electrode is modified with nanogold-carbon nano tube-chitosan with a self-assembly method, mouse macrophages Ana-1 endocytosing magnetic nanoparticles are taken as a sensing medium and directly adsorbed by the modified electrode, and the sensor is constructed; finally, the sensor is applied to lipopolysaccharide toxicity evaluation of the Gram-negative bacteria, has the obvious toxic effect change with the lipopolysaccharide concentration in the concentration range of 1-5 mu g mL<-1>, and has the detection limit of 0.3 mu g mL<-1>. The toxicity of the Gram-negative bacteria is detected with the method efficiently, conveniently and quickly, defects of traditional toxicity detection methods of the pathogenic bacteria are overcome, and the obtained sensor is simple to prepare, convenient to operate and low in cost and has the bright application prospect in the aspect of evaluation of the toxicity of the pathogenic bacteria.

The invention discloses a dexamethasone-entrapped macrophage-derived microvesicle as well as a preparation method and application thereof. The dexamethasone-entrapped macrophage-derived microvesicle is formed by entrapping dexamethasone by a microvesicle from a cell RAW 264.7 of a mouse macrophage system. The dexamethasone-entrapped macrophage-derived microvesicle disclosed by the invention can beuptaken by an injured cell more effectively, and fulfills the aim of improving the kidney inflammation by inhibiting the activation of a proinflammatory signal pathway and infiltration of inflammatory cells. Meanwhile, the preparation method disclosed by the invention is simple, convenient and efficient; the prepared microvesicle is from the cell RAW 264.7, so that sufficient microvesicles can beprovided, and the microvesicles are wide in source; large-scale production can be implemented. The dexamethasone-entrapped macrophage-derived microvesicle prepared through the preparation method disclosed by the invention can be applied to preparation of a drug or preparation for treating kidney diseases and can also be applied to preparation of an anti-inflammatory or immunosuppression drug or preparation.

The invention relates to the field of a preparation method and application of a traditional Chinese medicine effective component and in particular relates to a preparation method of rhizoma polygonatipolysaccharide and application of the rhizoma polygonati polysaccharide to the preparation of an immunological enhancement medicine. The rhizoma polygonati polysaccharide is obtained by processing raw rhizoma polygonati, extracting and separating; when an extraction method provided by the invention is adopted, the extraction rate of the rhizoma polygonati polysaccharide is high and the content oftotal polysaccharide is high; the proliferation activity of the rhizoma polygonati polysaccharide on normal mouse spleen cells is improved; cyclophosphamide induced spleen and thymus gland index of mice with low immunity also can be improved; the in-vitro proliferation capability of spleen and thymus gland cells under the stimulation of concanavalin A is enhanced; the phagocytic function of macrophage of the mice with the low immunity and the capability of secreting IL-6 and TNF-alpha are enhanced; the rhizoma polygonati polysaccharide has actual application value in the aspect of treatment of diseases including immunodeficiency diseases, tumors and the like.

The invention provides an extracting purification method for rhizoma anemarrhenae polysaccharide. The method comprises the steps that rhizoma anemarrhenae powder is subjected to degreasing, water extraction and alcohol precipitation extraction through an organic solvent to obtain crude rhizoma anemarrhenae polysaccharide; low-molecular-weight impurities are removed through dialysis of a dialysis membrane, a rhizoma anemarrhenae polysaccharide analysis solution is obtained through adsorption and separation of a DEAE-agarose gel column, and dialysis of the dialysis membrane is adopted for obtaining refined components of the rhizoma anemarrhenae polysaccharide. The invention provides the extracting method for the refined components of the rhizoma anemarrhenae polysaccharide for the first time, compared with a traditional method, and the refined components of the rhizoma anemarrhenae polysaccharide obtained through the method have the higher excitation capability than that of mouse macrophage RAW264.7, and the higher excitation effect for promoting expression of iNOS and related cell factors mRNA.

The invention discloses a method for capturing high-purity circulating tumor cells based on a biological orthogonal chemical method. The method comprises the following steps: s1, preparing superparamagnetic ferroferric oxide nanoparticles; s2, preparing a bionic magnetic vesicle; s3, performing functional modification on the bionic magnetic vesicles; s4, growing azide genes on the surfaces of thetumor cells; and s5, capturing the circulating tumor cells. After superparamagnetic ferroferric oxide nanoparticles and macrophages are incubated, bionic magnetic vesicles can be generated through mouse macrophages in a way similar to exosome release, and then functional modification is carried out; tumor cells generate functional groups on the surfaces of cell membranes in advance through intracellular metabolism of the tumor cells, the tumor cells are incubated with the functionalized magnetic vesicles, the two functional groups are combined through bioorthogonal chemistry, capture of circulating tumor cells is achieved, and the mode has the potential of being applied to liquid biopsy.

The invention provides a lentinan calcium complex, and a preparation method and application thereof. The method comprises the steps of: adding a calcium chloride solution to an aqueous solution of lentinan with stirring, at 40-80 DEG C, regulating a pH value to 7-10 with sodium hydroxide, and continuously stirring for 1 h for a complex reaction; removing free calcium ions by a dialysis method; and concentrating and freeze-drying the lentinan compound solution to obtain the lentinan calcium complex with calcium content of 5.2mg / g. Compared with a blank group, the lentinan calcium complex can obviously promote mouse macrophage RAW264.7 to release immune factors, such as a tumor necrosis factor TNF-alpha and a cell factor IL-6. The preparation method of the lentinan calcium complex provided by the invention is simple and easy for practice. Besides, as an organic calcium, the lentinan calcium complex can also promote calcium absorption and improve immunity.

The invention discloses a gene associated with the toxicity of Brucella and application of the gene in evaluation of the toxicity of the Brucella and preparation of low-toxicity Brucella. By using a homologous recombination method, a ribosome gene L31 of the Brucella M28 is replaced by a kanamycin gene, and a Brucella L31 gene deletion strain M28deltaL31 is obtained. By using macrophages RAW264.7and a Babl / c mouse model, the influence of the Brucella L31 gene on the toxicity of the Brucella M28 is evaluated. Through results, it is shown that after the L31 gene is deleted, the growth of the M28 cannot be affected, but the duplication survival capacity of the high-toxicity strain M28 in the mouse macrophage system RAW264.7 and the mouse spleen can be obviously reduced, after the L31 gene issupplemented in the M28deltaL31, the toxicity can recover to the level of a wild strain, and it is proved that the gene is associated with the toxicity of the Brucella M28. The gene for predicting the toxicity can be used for research and development of new brucella vaccines, and the gene has a potential application value.

The invention provides application of myricanol and / or myricetin to preparation of a medicine for preventing and / or treating inflammatory bowel diseases. The inflammatory bowel diseases are treated through the myricanol and / or the myricetin. The myricanol and / or the myricetin have / has an inhibition effect on IL-6, TNF-alpha and IL-1beta inflammatory factors secreted by RAW264.7 cells of mouse macrophage in vitro, and inhibition on expression of inflammatory factors is generated; more particularly, the myricanol and / or the myricetin have / has an inhibition effect on the inflammatory bowel diseases and have no obvious toxic and side effects in a medicinal effect expressing process; the ulcer area is effectively reduced. Compared with existing aminosalicylic acid medicines, the myricanol and / or the myricetin have / has a better curative effect and are / is suitable for large-scale production; the myricanol and / or the myricetin have / has a wide application prospect and relatively high application value.

The invention relates to a macrophage-mediated drug-loaded hyaluronic acid nanohydrogel and preparation thereof. A drug-loaded hyaluronic acid nanohydrogel is obtained by synthesizing polypyrrole in situ from the interior of a hyaluronic acid nanohydrogel, and loading a drug; and the macrophage-covered drug-loaded nanohydrogel is obtained by performing co-incubation on the drug-loaded hyaluronic acid nanohydrogel and mouse macrophages. The macrophage-mediated drug-loaded nanohydrogel prepared by the method has the advantages of low toxicity, safety, avoidance of phagocytosis of a reticuloendothelial system, and specific targeting in tumor areas when used for delivery of anti-cancer drugs, and has potential application prospects in tumor treatment.

The invention discloses dendrobium officinale leaf fermented wine which is prepared from fresh dendrobium officinale leaves, olive fruits, white granulated sugar, bacteria powder and distilled water according to certain weight part proportions, wherein the bacteria powder is prepared by mixing lactobacillus plantarum, rhamnose bacteria, lactic acid bacteria DU-106, saccharomycetes, NaCl, glucose,inulin and dietary fiber according to proportions. The preparation method of the dendrobium officinale leaf fermented wine comprises the following steps: raw material selection; blanching with boiledwater; preparation of alcohol liquid; diastatic fermentation; aging fermentation; clarification and degerming; distillation of the alcohol liquid to obtain the dendrobium officinale leaf fermented wine. The dendrobium officinale leaf fermented wine has mellow wine flavor. Tastes smooth and mellow, and has sour-sweet and tasty taste; the wine is light pink, clarified, stable and uniform. The dendrobium officinale leaf fermented wine has nutritional effects of the fresh dendrobium officinale leaves, and also has physiological and health-care effects achieved by fermentation and metabolism of lactic acid-production bacillus and saccharomyces cerevisiae. The alcohol content is 6 to 15 percent, the total acid content is 0.5 to 1.5 percent, and the polysaccharide content is 0.5 to 0.8 percent. The dendrobium officinale leaf fermented wine has an outstanding immunobiological activity; the phagocytosis activity of RAW 264.7 mice macrophage and the secretion volume of relevant immunocytokines can be improved.

The invention discloses a preparation method and application of a novel C19-diterpene alkaloid separated from buttercup Aconitum plant Aconitum taronense. By using the root of Aconitum taronense as a raw material, the novel C19-diterpene alkaloid taronenine A is separated and identified by using an acid water penetrating method, a solvent extraction method, column chromatography on silica gel and a spectroscopy method, in vitro anti-inflammatory experiments indicate that the compound has an obvious effect for inhibiting lipopolysaccharide mediated mouse macrophage RAW 264.7 from releasing skin reaction factor interleukin-6, and the foundation is established for developing novel anti-inflammatory drugs from the plants.

The invention discloses the use of anthocyanin in medicines for treating atherosclerosis and the application for preventing and treating atherosclerosis with regulation and control of CHOP gene, and relates to the improvement effect of anthocyanin monomer cyanidin-3, 5-diglucoside on macrophage injuries caused by oxidized low density lipoprotein, and discusses the mechanism of action thereof. In the invention, mouse macrophage cell line RAW264.7 is tested, and the effect of cyanidin-3, 5-diglucoside on activity of RAW264.7 macrophage processed by the oxidized low density lipoprotein is determined based on MTT method, the total RNA of cells is extracted, Affymetrix Mouse U4302.0 gene expression profile chip is applied to carry out marking hybridization experiments, differential gene analysis is carried out for the scanning results of Affyemtrix gene chip with MTT method, and the differential genes are screened, and further real-time quantitative PRC method is utilized to further validate the expressed differential gene, The validation results verify that the cyanidin-3, 5-diglucoside can regulate CHOP gene expression down, and has obvious protective action on macrophages injured by oxidized low density lipoprotein.

The invention provides a new flavone compound with a structure shown by a formula (I) in the specification, a preparation method thereof and an application thereof in skin whitening and / or anti-inflammation. The new flavone compound can significantly inhibit tyrosinase activity and the nitrogen oxide metabolism of LPS induced mice macrophage RAW 264.7, therefore, the new flavone compound provided by the invention can be hopefully used for preparing medicaments with skin whitening and anti-inflammation effects, and a new thought is provided for researching and developing medicaments, health products, daily chemical products and the like with skin whitening and anti-inflammation effects.

The invention relates to application of a novel phenolic acid compound in preparation of an anti-inflammatory drug, and also relates to a preparation method for extracting, separating and purifying the compound from a traditional Chinese medicine sabia parviflora. Pharmacological research shows that the novel compound can remarkably inhibit the levels of NO, IL-1, IL-6 and TNF-alpha in mouse macrophages RAW246.7 caused by lipopolysaccharide (LPS), and the inhibition effect is mostly dependent on a dose, so the compound has obvious anti-inflammatory activity and can be used for preparing anti-inflammatory drugs. The preparation method is simple and easy to implement, and the obtained compound is high in purity and has good economic benefits and application prospects.

The invention discloses a comprehensive model for protecting mice and curing mice macrophage system UC (Ulcerative Colitis) by C-BF (Cathelicidin-BF). C-BF has broad-spectrum antibacterial activity, especially for gram-negative bacteria. IBDS (Inflammatory Bowel Diseases) include UC and CD (Crohn's Disease), and the pathological mechanisms of IBDS are not clear. The comprehensive model provided by the invention combines in-vivo mice experiments and in-vitro cell experiments to evaluate the effects of C-BF on relieving inflammations, reducing the cell apoptosis level and improving the intestinal barrier function.

The invention provides an antimicrobial peptide derived from scorpion venom as well as a preparation method and application of the antimicrobial peptide. The antimicrobial peptide RLL has a sequence shown as SEQ ID No.1. A peptide RSN is obtained by intercepting 14 amino acids in the middle of the scorpion toxin, negatively charged aspartic acid in the peptide RSN is replaced with positively charged arginine, and serine, glycine and asparagine in a peptide chain are replaced with leucine to obtain the antimicrobial peptide RLL; and the antimicrobial peptide RLL has very low hemolytic activityand eukaryotic cytotoxicity, the antimicrobial peptide cannot cause 10% erythrocyte hemolysis at a concentration of 128 [mu]mol / L, the survival rate of mouse macrophages RAW 264.7 reaches 80% or more,and the antimicrobial peptide has the development potential of becoming an antibiotic substitute.

The invention relates to a separating and purifying method for preparing white muscardine silkworm anticancer-activity polysaccharide BBPW-1, which comprises the following steps: degreasing white muscardine silkworm powder under reflux of acetone-petroleum ether and 80% ethanol to remove glycosides and alkaloids, and extracting with distilled water at 80-100 DEG C to obtain crude polysaccharide; and after removing proteins from the crude polysaccharide by a Sevag process, separating out the neutral polysaccharide component by DEAE (diethylaminoethanol) sepharose ion-exchange chromatography, carrying out propylene dextrangel S-300 chromatography, taking the first eluting peak, concentrating under reduced pressure, carrying out propylene dextrangel S-500 chromatography for further purification, and carrying out freeze-drying to obtain the white muscardine silkworm anticancer-activity polysaccharide BBPW-1. The product prepared by the method provided by the invention has uniform purity, and the molecular weight is 3.67*10<6>Da; and the product has an inhibiting action on growth of human cervical cancer cells Hela and human liver cancer cells HepG2, does not have any adverse effect on growth of normal human embryo kidney cells HEK293 and mouse macrophages RAW264.7, and can be used for developing anticancer products.

The invention discloses traditional Chinese medicine with an immunity enhancing function. The traditional Chinese medicine is prepared from five types of Chinese medicinal materials, namely, Chinese yam, barbary wolfberry fruit, Chinese angelica, Chinese date and donkey-hide gelatin. As proven by pharmacodynamic test, the traditional Chinese medicine has the effects of remarkably raising the serum hemolysin titer level of a mouse, improving the macrophage phagocytosis capability of the mouse and promoting the NK cell activity of the mouse, and can be used for improving the immunologic function of the mouse. As proven by safety test, the formula is safer than brain-refreshing tea, is more scientific, and is more suitable for long-time taking.

The invention belongs to the technical field of Chinese traditional medicine application, and specifically relates to application of chrysin to preparation of drugs for treating obesity-related metabolically triggered inflammations. According to the invention, the chrysin promotes the replacement activation of IL-4 activated mouse macrophages, promotes the release of anti-inflammatory cytokines IL-10, and promotes the rise of enzyme activity of typical labeled molecule arginine for the replacement activation of the macrophages, the up-regulation of surface molecules MGL1 / 2 and the up-regulation of classical molecules CD206, Ym1 and Fizz. Especially, in fat mice C57 / B6 induced by high-fat feeding, the chrysin is capable of inhibiting the release of proinflammatory cytokines TNF-alpha, AST (Aspartate Transaminase) and ALT (Alanine Transferase) in blood serum, increasing the release of the anti-inflammatory cytokines IL-10, alleviating the lesion of liver and adipose tissues, inhibiting the phagocytic function of the peritoneal macrophages, the antigen presentation ability and the release ability of NO, and lowering the expression of the typically activated surface molecules CCR7 and CD80 of the macrophages. According to the invention, a new drug for treating the obesity-related metabolically triggered inflammations is developed.

The invention relates to a method for manufacturing phenolic acid positions of vernonia anthelmintica and anti-inflammation application of the phenolic acid positions. The method includes smashing dried fruits of the vernonia anthelmintica; extracting extracts by the aid of organic solvents; separating and purifying the extracts by the aid of resin to obtain the phenolic acid positions of the vernonia anthelmintica. Main active ingredients of phenolic acid at the positions of the vernonia anthelmintica include 3, 4-dicaffeoyl-quinic acid, 3, 5-dicarffeoyl-quinic acid and 4, 5-dicaffeoyl-quinic acid, the total content of the phenolic acid ranges from 20% to 99%, excess release of nitric oxide of inflammation mediators can be obviously suppressed by the phenolic acid positions of the vernonia anthelmintica in inflammation response of mice macrophage RAW264.7 induced by lipopolysaccharide, excessive secretion of interleukin 6, interleukin 1 and tumor necrosis factors alpha of inflammation factors can be suppressed, excess expression of nitric oxide synthase and epoxidase 2 can be suppressed, and phosphorylation of nuclear factors kB can be suppressed. The method has the advantages that the phenolic acid positions of the vernonia anthelmintica has excellent anti-inflammation activity and can be used for preventing or treating inflammation due to the excess nitric oxide, the excess tumor necrosis factors alpha, the excess interleukin 6 or the excess interleukin 1.

The invention discloses a monoterpene compound as well as a preparation method and application thereof. The monoterpene compound is obtained by taking chenopodium ambrosioides leaves as a raw material, extracting extract, extracting with an organic solvent, carrying out silica gelcolumn chromatography, carrying out Sephadex LH-20 column chromatography and carrying out high pressure liquid chromatography separation, wherein the molecular formula of the compound is C10H16O2, the compound is named 4-hydroxy-4-isopropyl-2-methyl-2-cyclohexene-1-one, and the compound has a structure (described in the specification). The preparation method comprises the following steps: by taking the chenopodium ambrosioides leaves as the raw material, extracting the extract, extracting with the organic solvent, carrying out the silica gelcolumn chromatography, carrying out the Sephadex LH-20 column chromatography and carrying out the high pressure liquid chromatography separation, so that the monoterpene compound is obtained. The application is namely application of the monoterpene compound in preparation of a drug used for preventing and / or inflammation. In vitro anti-inflammation activity tests are carried out on the monoterpene compound, and experimental results show that the monoterpene compound has good effect of inhibiting lipopolysaccharide (LPS)-induced mouse macrophage (RAW264.7) from producing nitric oxide (NO) and can provide a lead compound with application value for medical industry.

The invention relates to an age-related complementary food nutrition bag rich in hypoallergenic heterologous immunocompetence peptides and a preparation method thereof, and belongs to the technical field of age-related nutrition supplement food. Twelve nutrient supplement factors are formed on three low-sensitization protein-based carriers, namely sea cucumber protein peptide powder, terrestrial plant source-soybean protein peptide powder and terrestrial animal source high-quality protein-skimmed milk powder for the first time; I-level steady-state protection of nutrient supplementation factors, II-level steady-state protection formed on a low-sensitization protein-based carrier and a III-level steady-state protection technology of double quantitative precise filling are designed, and the senile complementary food nutrition bag rich in the low-sensitization heterologous immunocompetence peptide is created; and the symbolic characteristics of low sensitization, high immunocompetence and high stability of the compound are confirmed through inspection of three indexes including a BALB / C mouse sensitization evaluation model, a mouse macrophage RAW264.7 cell model and the decay rate of vitamin A acetate, cholecalciferol and cyanocobalamin, and technical support is provided for development of series products.

The invention provides a preparation method for maca polysaccharide and preliminary study on immunoregulatory activity thereof. The maca polysaccharide of a relatively high purity is extracted and separated by various means such as boiling water extraction, ethanol precipitation and passing DEAE-52 cellulose resin. Mmonosaccharide is detected to comprise glucose and arabinose with a molar ratio of (4-10): 1 and the molecular weight of the monosaccharide is 10000-30000Da. Meanwhile, the polysaccharide extracted by the method provided by the invention has certain promoting action on activity of a mouse macrophage RAW264.7 and expression of TLR4, TLR2 and an inflammatory factor of the mouse macrophage. The invention has characteristics that the process flow is simple, the operation is easy, the cost is relatively low, and large-scale production is facilitated; the polysaccharide extracted by the method provided by the invention has functions of preventing and resisting cancers, resisting aging, resisting oxidization, resisting autoimmune diseases and the like, thereby providing a theoretical basis for further researching and developing polysaccharide new drugs.

The invention relates to an application of sulfated chlorella and spirulina composite polysaccharides in the immunoloregulation field. The sulfated composite polysaccharides have immunoloregulation activity, can enhance the neutral red phagocytosis ability of macrophages in mice, can improve the NO production ability of the macrophages and significantly improve the proliferation of splenic lymphocytes in the mice, and can improve the DNFB induced delayed allergy of the mice to enhance the immunity of the mice.

The invention discloses a preparation method of mulberry twig antineoplastic activity polysaccharide RMPW-1. The method comprises the steps of removing small molecular substances such as glycoside and alkaloid of mulberry twig powder by performing backflow and degreasing on petroleum ether and backflow of ethyl alcohol, then extracting crude polysaccharide by double distilled water, removing protein by the Sevag method, precipitating with ethyl alcohol twice in sequence, separating an acid polysaccharide component by DEAE sepharose gel ion-exchange column chromatography, desalting by propylene sephadex S-100 chromatography, collecting eluant corresponding to the first eluting peak through propylene sephadex S-300 chromatography, concentrating under reduced pressure, and freezing and drying in vacuum to obtain the product. The product prepared in the invention is uniform in purity, has a molecular weight of 1.37*10<5>Da, has an obvious inhibition effect on the growth of human cervical carcinoma cells Hela and human gastric carcinoma cells SGC-7901, has no adverse influence on the growth of human embryo nephrocyte HEK293 and mouse macrophage RAW264.7, and can be used for the development of antitumor products.

The invention discloses a small RNA (ribonucleic acid) related to virulence of Brucella and application of the small RNA in preparation of the weak virulence Brucella. The application Northern blot proves an sRNA Clu7 exists in a virulent Brucella strain M28, a sRNA defective strain M28 delta Clu7 is constructed by adopting a homologous recombination method, and the affection of the sRNA on the virulence of the M28 is evaluated by taking a mouse macrophage RAW264.7 and a Balb / c mouse as models. A result shows that the replication capability and the survival capability of the virulent strain M28 in the mouse macrophage RAW264.7 and the mouse can be remarkably reduced after deficiency of the sRNA. When in a fifth week of inoculation, the M28 delta Clu7 is completely eliminated from a body ofthe mouse, and the virulence of the M28 delta Clu7 is remarkably lowered in comparison with the M28. A mouse virulence attacking protection experiment shows that the protection effect that the mouseresists the infection of the virulent strain M28 by the immune M28 delta Clu7 can reach the protection force of a vaccine strain M5-90. The results indicate that the sRNA Clu7 has a significant decisive effect on the virulence of the Brucella. The small RNA has a significant promoting effect on a mechanism of disclosing the virulence of the Brucella. According to the small RNA, a novel technical means is provided for research and development of a novel candidate vaccine strain of the Brucella.

The invention discloses an iridoid glycoside compound, which is a novel chemical component discovered from cape jasmines. The compound separated by virtue of the method is further structurally identified by virtue of measures of physicochemical properties and modern spectroscopy. Activity evaluation is further carried out by virtue of activity screening systems such as an LPS-induced RAW 264.7 cell inflammation model so as to discover that the compound has a certain protecting effect on a mouse macrophage system RAW 264.7, is capable of remarkably inhibiting PGE2 and presents a relatively strong anti-inflammatory action.

The invention provides application of myricanol and / or myricetin to preparation of a medicine for preventing and / or treating inflammatory bowel diseases. The inflammatory bowel diseases are treated through the myricanol and / or the myricetin. The myricanol and / or the myricetin have / has an inhibition effect on IL-6, TNF-alpha and IL-1beta inflammatory factors secreted by RAW264.7 cells of mouse macrophage in vitro, and inhibition on expression of inflammatory factors is generated; more particularly, the myricanol and / or the myricetin have / has an inhibition effect on the inflammatory bowel diseases and have no obvious toxic and side effects in a medicinal effect expressing process; the ulcer area is effectively reduced. Compared with existing aminosalicylic acid medicines, the myricanol and / or the myricetin have / has a better curative effect and are / is suitable for large-scale production; the myricanol and / or the myricetin have / has a wide application prospect and relatively high application value.